Biologics Face Tougher Patent Scrutiny After Amgen Ruling
A recent Federal Circuit decision clamping down on broad antibody patent claims may have some biologics makers scrambling to save their existing intellectual property and questioning whether to patent future drugs...To view the full article, register now.
Already a subscriber? Click here to view full article